University of Alabama at Birmingham
Birmingham, Alabama, 35205, United States
Location status: Recruiting
Location contact
Kenneth G. Saag, MD
PRINCIPAL_INVESTIGATOR
Lesley E. Jackson, MD
SUB_INVESTIGATOR
Zac Armor
CONTACT
NCT Number: NCT06534554
The prevalence of gout has been steadily increasing over several decades and is correlated with the rising burden of obesity, chronic cardiac and renal disease; all conditions overrepresented in the Southeastern U.S. - particularly in African Americans. Through a novel post-emergency department visit intervention, we aim to improve the care patients with gout receive, both during acute exacerbations and long-term. A secondary goal of the project is to concurrently enhance participation of minorities in biomedical research in the Deep South.
Interested in participating?
Request Info18 year–99 year
All sexes
Interventional
Not applicable
Birmingham, Alabama, 35205, United States
Location status: Recruiting
Kenneth G. Saag, MD
PRINCIPAL_INVESTIGATOR
Lesley E. Jackson, MD
SUB_INVESTIGATOR
Zac Armor
CONTACT
The prevalence of gout has been steadily increasing and is correlated with the rising burden of obesity, chronic cardiac and renal disease; all conditions overrepresented in the Southeast U.S. - particularly in African Americans. Many patients with acute gout receive care at the emergency department (ED), particularly underserved urban populations in the Deep South. Appropriate outpatient follow-up for an acute flare after an ED visit is variable. Indeed, in a preliminary analysis of a retrospective cohort study of patients with acute gout treated at our urban medical center ED, only 46% of patients followed up with an outpatient clinician in our healthcare system within 6 months of their ED visit. Even fewer (36%) had an outpatient visit specifically addressing gout care within 6 months post-ED visit. This population of patients that seek acute gout care in the ED represent an important group that may benefit from interventions focused on improving gout quality of care, such as promoting outpatient follow-up.
While having a mechanism to identity acute gout patients in the ED is fundamental for enhancing care for patients with acute gout, recruiting people with acute gout who receive care in the ED outside regular business hours is challenging. One potential solution involves approaching patients after their ED visits remotely using patient navigators. The 36-72 hour period after their ED visit represents a critical time during which patients may be more receptive to efforts focused on improving healthy behaviors including scheduling outpatient follow-up (i.e., a "teachable moment). Patient navigators are trained, lay individuals of similar cultural background, and region, who provide personal guidance to patients and engage "hard-to-reach" groups, reduce access barriers, and encourage healthy behaviors such as engaging in outpatient chronic disease management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A lay patient navigator working will contact patients seen in the UAB ED via phone within ~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
Time frame: 3 months
Proportion of patients that have a follow-up visit addressing gout in the 3-month period after the ED visit.
Contact information is provided by the study sponsor or research team.
Lesley E. Jackson, MD
CONTACT
Zac Armor
CONTACT
University of Alabama at Birmingham
Other
Improving Gout Care After an Emergency Department Visit for Acute Gout
Acronym: CARE-Gout
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07535034
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Granada Hills, California, United States
View Trial DetailsNCT07089875
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT07280156
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Little Rock, Arkansas, United States
View Trial DetailsNCT05109936
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Caen, France
View Trial Details